5Chen S, Hong SW, Iglesias-delacruz MC, et al. The key role of transforming growth factor-beta system in the pathogenesis of diabetic nephropathy [ J ]. Ren Fail,2001,23 (3 -4):471
6Ball SG. Benefits of blood pressure reduction in diabetic patients[J]. J Hypertens Suppcl,2003,21 (6) :31
二级参考文献21
1Matsumoto K,Nakamura K.Hepatocyte growth factor:Renotropic role and potential therapeutics for renal diseases [J].Kidney Int Suppl,2001,59(6):2023-2038.
2StrutzF,HeegM,Kochsiek T,et al.Effects of pentoxifylline,pentifylline and gamma-interferon on proliferation,differentiation,and matrix synthesis of human renal fibroblasts[J].Nephrol Dil Transplant,2000,15(10):1535-1546.
3Peng H,Carrentero OA,Rajj L,et al.Antifibrotic effects of N-acetylseryl-aspartyl-lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats[J].Hypertension,2001,37 (2):794-800.
4Isaka Y,Tsujie M,Ando Y,et al.Transforming growth factor-beta 1antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction[J].Kidney Int Suppl,2000,58(5):1885-1892.
5Imai E,Akagi Y,Isaka Y.Towards gene therapy for renal diseases[J] .Nephrologie,1998,19(3):397-402.
6O' Donnell MP.Renal tubulointerstitial fibrosis.New thoughts on its development and progression[J].Postgrad Med,2000,108:159-162.
7Eddy AA.Molecular basis of renal fibrosis[J].Pediatr Nephrol,2000,15(3-4):290-301.
8Klahr S,Morrissey JJ.The role of vasoactive compounds,growth factors and cytokines in the progression of renal disease[J].Kidney Int Suppl,2000,57(suppl):7-14.
9Goumenos DS,Tsamandas AC,Oldroyd S,et al.Transforming growth factor-beta (1) and myofibroblasts:a potential pathway towards renal scarring in human glormerular disease[J].Nephron,2001,87(3).:240.
10Ranieri E,Gesualdo L,Grandaliano G,et al.The role of alpha-smooth muscle actin and platelet-derived growth factor-beta receptor in the progression of renal damage in human IgA nephropathy[J].J Nephrol,2001,14(4):253-262.
7Gruberg L, Dangas G, Mehran R, et al. Clinical outcome fol-lowing percutaneous coronary interventions in patients with chronic renal failure [J]. Catheter Cardiovasc Interv, 2002,55(1):66-72.
8Go AS, Chertow G M, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitaliza-tion[J]. N Engl J Med ,2004,351 (13):1296-1305.
9Santopinto J J, Fox KA, Goldberg R J, et al. Creatinine clear-ance and adverse hospital outcomes in patients with acute coronary syndromes:findings from the global registry of a-cute coronary events (GRACE) [J]. Heart, 2003,89 (9): 1003-1008.
10A1 SJ, Reddan DN, Williams K, et al. Prognostic implications of abnormalities in renal function in patients with acute coro- nary syndromes [J]. Circulation, 2002,106 (8):974-980.
